Back to Search Start Over

Covid-19 in liver transplant recipients: the French SOT COVID registry

Authors :
A. Mazzola
Lucy Meunier
Faouzi Saliba
Hélène Barraud
Vincent Leroy
Camille Besch
Maxime Mallet
Jérôme Dumortier
Mario Altieri
Sophie Caillard
Sylvie Radenne
Noémie Laverdure
Jean Philippe Richardet
Claire Vanlemmens
Pauline Houssel-Debry
Filomena Conti
Ilias Kounis
Marc Hazzan
Sébastien Dharancy
Claire Francoz
Florentine Garaix
Olivier Roux
François Durand
Christophe Duvoux
Audrey Coilly
Guillaume Lassailly
CCSD, Accord Elsevier
Hospices Civils de Lyon (HCL)
Hôpital Edouard Herriot [CHU - HCL]
Hôpital Henri Mondor
Hôpital Beaujon [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Hôpital Côte de Nacre [CHU Caen]
CHU Caen
Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)
CHU Trousseau [Tours]
Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Hôpital de Hautepierre [Strasbourg]
Immuno-Rhumatologie Moléculaire
Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Hôpital Paul Brousse
Physiopathologie et traitement des maladies du foie
Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Hôpital Claude Huriez [Lille]
CHU Lille
Hôpital de la Timone [CHU - APHM] (TIMONE)
CHU Pontchaillou [Rennes]
Hôpital Femme Mère Enfant [CHU - HCL] (HFME)
Hôpital Saint Eloi (CHRU Montpellier)
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Hôpital de la Croix-Rousse [CHU - HCL]
Hôpital JeanMinjoz
French Solid Organ Transplant COVID Registry
Groupe de Recherche Français en Greffe de Foie (GReF²)
Source :
Clinics and Research in Hepatology and Gastroenterology, Clinics and Research in Hepatology and Gastroenterology, 2021, 45 (4), pp.101639. ⟨10.1016/j.clinre.2021.101639⟩
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Highlights • Coronavirus disease-2019 (Covid-19) is an ongoing global pandemic of major concern; available data on clinical presentation and prognosis in liver transplant (LT) recipients remains limited. • Disease presentation, immunosuppression management, clinical outcomes, and prognostic factors in 104 French LT recipients (91 adults) with Covid-19 are reported. • The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients. • The 30-day mortality rate of all adult patients was 20.0%, and 28.1% for hospitalized patients.<br />Background Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in organ transplant recipients remains limited. The aim of this registry-based observational study was to report the characteristics and clinical outcomes of liver transplant (LT) recipients included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19. Methods COVID-19 was diagnosed in patients who had a positive PCR assay for SARS-CoV-2 or in presence of typical lung lesions on imaging or specific SARS-CoV-2 antibodies. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded. Results Of the 104 patients, 67 were admitted to hospital and 37 were managed at home (including all 13 children). Hospitalized patients had a median age of 65.2 years (IQR: 58.1 − 73.2 years) and two thirds were men. Most common comorbidities included overweight (67.3%), hypertension (61.2%), diabetes (50.7%), cardiovascular disease (20.9%) and respiratory disease (16.4%). SARS-CoV-2 infection was identified after a median of 92.8 months (IQR: 40.1 − 194.7 months) from LT. During hospitalization, antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively. The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients. The 30-day mortality rate was 20.0%, and 28.1% for hospitalized patients. Multivariate analysis identified that age was independently associated with mortality. Conclusion In our large nationwide study, Covid-19 in LT recipients was associated with a high mortality rate.

Details

Language :
English
ISSN :
22107401 and 2210741X
Database :
OpenAIRE
Journal :
Clinics and Research in Hepatology and Gastroenterology
Accession number :
edsair.doi.dedup.....08d380e7b9c9de2c63daa26c621ea00d
Full Text :
https://doi.org/10.1016/j.clinre.2021.101639